Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Enrolling treatment-naive patients in Parkinson’s disease clinical trials

Milton Werner, PhD, Inhibikase Therapeutics, Inc., Atlanta, GA, discusses the challenges and significance of enrolling treatment-naive patients in Parkinson’s disease clinical trials. Because there are currently no medications available to modify the course of the disease, it is crucial to study individuals who have not taken any medications. These patients provide a clear baseline for evaluating the efficacy of new drugs. Dr Werner also shares his optimism about the potential impact of these medications, stating that the goal is to change or slow the progression of the disease, ultimately improving the quality of life and functionality of patients. However, he highlights that the increasing use of telehealth and early symptom management with other medications is making it more challenging to find treatment-naive participants. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Milton Werner reports the following disclosures:
Founder and largest shareholder, Inhibikase Therapeutics, Inc.